{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreie5iqkeflafhmveqpygn4vfqt4bal4z4idbu26dac57aagryuga4i",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mflxdcwgow72"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidwxon445245umcghzuvjiratvehuzkh66gu2cw7qjgebvci6ll4q"
    },
    "mimeType": "image/jpeg",
    "size": 669852
  },
  "path": "/news/2026-02-drug-candidate-preterm-birth-preclinical.html",
  "publishedAt": "2026-02-24T04:33:51.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Obstetrics & gynaecology"
  ],
  "textContent": "New research shows that Rytvela, an anti-inflammatory drug candidate, decreased premature birth and infant mortality when administered after the onset of preterm labor in a preclinical mouse model. The current standard treatment for preterm labor, Nifedipine, failed to confer similar benefits.",
  "title": "New drug candidate prevents preterm birth in preclinical studies"
}